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Immunogenicity and Safety of a Live Attenuated Zoster Vaccine 
(ZOSTAVAXTM) in Korean Adults
A live attenuated zoster vaccine (ZOSTAVAXTM, Merck & Co. , Inc.) was approved by the 
Korea Ministry of Food and Drug Safety in 2009. However, the immunogenicity and safety 
of the vaccine has not been assessed in Korean population. This is multi-center, open-label, 
single-arm study performed with 180 healthy Korean adults ≥ 50 yr of age. The geometric 
mean titer (GMT) and geometric mean fold rise (GMFR) of varicella zoster virus (VZV) 
antibodies were measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) 
at 4 weeks post-vaccination. Subjects were followed for exposure to varicella or herpes 
zoster (HZ), the development of any varicella/varicella-like or HZ/HZ-like rashes, and any 
other clinical adverse experiences (AEs) for 42 days post-vaccination. For the 166 subjects 
included in the per-protocol population, the GMT at Day 1 was 66.9. At 4 weeks post-
vaccination, the GMT for this population was 185.4, with a GMFR of 2.8 (95% CI, 2.5-
3.1). Of the 180 subjects vaccinated, 62.8% experienced ≥ 1 AE, with 53.3% of subjects 
reporting injection-site AEs. The most frequently reported injection-site AEs were erythema 
(45.0%) with the majority being mild in intensity. Overall, 44 (24.4%) subjects experienced 
≥ 1 systemic AE, 10 (5.5%) subjects experienced a systemic vaccine-related AE, and 3 
(1.7%) subjects experienced ≥ 1 serious AE not related to vaccine. No subjects reported a 
VZV-like rash. There was no subject of death and no subject discontinued due to an adverse 
event. A single dose of zoster vaccine induced VZV-specific gpELISA antibody response and 
was generally well-tolerated in healthy Korean adults ≥ 50 yr of age (registry at www.
clinicaltrial.gov No. NCT01556451).
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INTRODUCTION
Herpes zoster (HZ) is a disease occurring after first infection by 
varicella-zoster virus (VZV), due to reactivation of latent viruses 
remaining in sensory ganglion of cranial or spinal nerves. HZ 
causes pain and vesicular skin lesions along the unilateral der-
matome. The cumulative lifetime incidence of HZ is as high as 
about 10%-30% (1,2). The incidence of HZ increases with age 
(3-9). The incidence of complications, such as post-herpetic 
neuralgia (PHN), increases in the elderly (4,5,10). The occur-
rence of HZ considerably lowers the quality of life and exacts 
high socioeconomic cost (8,11-14). 
 A live attenuated zoster vaccine (ZOSTAVAXTM, Merck & Co., 
Inc.) has been developed for the prevention of HZ and its com-
plications, especially herpes zoster associated pain and PHN. 
The Shingles Prevention Study (SPS) performed with subjects 
≥ 60 yr of age demonstrated that the use of the HZ vaccine re-
duced the incidence of HZ and PHN by 51.3%, and 66.5%, re-
spectively (15). The Zostavax Efficacy and Safety Trial (ZEST) 
performed with subjects 50-59 yr of age showed the vaccine re-
duced the risk of developing zoster by 69.8% (16).
 ZOSTAVAXTM was approved by the Korea Ministry of Food 
and Drug Safety in 2009 for the prevention of HZ in adults ≥ 60 
yr of age, with an expanded indication for adults ≥ 50 yr of age 
in 2011. This study (NCT01556451; V211-034) evaluated the im-
munogenicity, safety, and tolerability of the vaccine when ad-
ministered to Korean adults ≥ 50 yr of age.
MATERIALS AND METHODS
Study design
This was a multi-center (9 sites in Korea) open-label, single-arm, 
phase 4 study conducted from April 2012 to October 2012.
Study population
Healthy adults ≥ 50 yr of age on the day of signed informed con-
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sent were eligible. All subjects were afebrile ( < 38.0°C) on the 
day of vaccination and any underlying chronic illness needed 
to be stable. All females were postmenopausal or had a nega-
tive urine pregnancy test. Subjects were excluded if they had 
previous vaccination with any VZV-containing vaccine, history 
of hypersensitivity reaction to any vaccine component, history 
of HZ, immunodeficiency associated with illness or medical 
treatments, known or suspected active untreated tuberculosis, 
received immunoglobulin or any blood products during the 5 
months prior to vaccination or expected during 4 weeks post-
vaccination period, received any other live virus vaccine within 
4 weeks prior to vaccination or expected during 6 weeks post-
vaccination period, received any inactivated vaccine within 7 
days prior to vaccination or expected during 6 weeks post-vac-
cination period, or used any non-topical antiviral therapy with 
activity against herpes viruses. Subjects who received any pneu-
mococcal polysaccharide vaccine within 4 weeks prior to vacci-
nation or expected to receive any pneumococcal vaccine poly-
valent during the 42-day duration of the study were also excluded.
Study procedure
Subjects were vaccinated with the zoster live vaccine (ZOSTA-
VAXTM, Merck & Co., Inc.) on day 1 and followed for exposure to 
varicella or HZ or development of any varicella/varicella-like or 
HZ/HZ-like rashes, as well as any other clinical adverse experi-
ences for 42 days post-vaccination. Blood samples were obtain-
ed from all subjects immediately before vaccination and at 4 
weeks post-vaccination. Injection-site reactions, rashes, other 
adverse experiences, other concomitant medications, and con-
comitant vaccinations were recorded by the subject on a Vacci-
nation Report Card (VRC). This study was supported using the 
Merck Research Laboratories (MRL), One Merck Drive, P.O. 
Box 100, Whitehouse Station, NJ 0889-0100 USA, for procedures 
relative to initiation, monitoring, data handling, clinical supply 
management, safety management, and clinical study result re-
porting.
Immunologic measurements
The key immunogenicity outcome measures were the geomet-
ric mean fold rise (GMFR) of subjects’ VZV antibody titers from 
pre-vaccination to 4 weeks post-vaccination and geometric 
mean titer (GMT) at 4 weeks postvaccination. The VZV anti-
body titer was assessed by glycoprotein enzyme-linked immu-
nosorbent assay (gpELISA) at a central laboratory. The method 
detected antibodies to VZV glycoprotein (gp), purified from 
MRC-5 cells infected with the KMcC strain of VZV by lectin af-
finity chromatography. The reactivity of sera to the gp antigens 
from uninfected MRC-5 cells, denoted as tissue culture control 
(TCC) wells, was substracted from the reactivity of the sera to 
the gp antigens purified from VZV-infected MRC-5 cells. For 
the gpELISA, VZV gp or TCC antigen was absorbed to polysty-
rene microtiter wells and used as the solid phase antigen. Ex-
perimental, control, and standard curve sera (serum sample for 
reference standard curve) were incubated in VZV gp-coated 
and TCC-coated wells. Regarding standard curve performance, 
a single human serum sample with a high titer was used as a 
standard in the gpELISA. Within each validation run, the stan-
dard was tested in nine, twofold serial dilutions, ranging in con-
centration from 0.3125 to 80 gpELISA units/mL. For each se-
rum sample, a delta optical density (DOD) was calculated as 
the difference between the average optical density (OD) of the 
2 VZV antigen wells and the average OD of the 2 TCC wells. 
Quantitation was performed by comparison of sample DOD 
with a standard curve.
Safety measurements
Safety and tolerability data was collected for all subjects for 42 
days post-vaccination. Each subject was given a VRC to docu-
ment injection-site adverse events (AEs), systemic clinical AEs, 
concomitant medications, and oral temperatures (only if feel-
ing feverish) noted during the 42-day post-vaccination period. 
All serious adverse events occurring through day 42 post-vacci-
nation were to be reported by the investigator within 24 hr of 
first notification to the study site personnel.
 Severity of injection-site AEs except erythema and swelling, 
were classified as mild, moderate, and severe. Mild AE was de-
fined as an event causing no or minimal interference with usual 
social and functional activities. Moderate AE was defined as an 
event causing greater than minimal interference with usual so-
cial and functional activities. Severe AE was defined as an event 
causing inability to perform usual social and functional activi-
ties. Injection site erythema and swelling was measured to es-
tablish the maximum size.
 Subjects who develop suspected varicella/varicella-like or 
HZ/HZ-like rashes were to notify the investigator immediately. 
The subjects were planned to be seen by the investigator at the 
study site within 72 hr of rash onset (preferably within 24 hr) for 
clinical evaluation. Polymerase chain reaction assay was 
planned to detect VZV and herpes simplex virus (HSV) deoxy-
ribonucleic acid (DNA) in specimens obtained from subjects 
suspected of having varicella or HZ.
Statistical methods
This study was descriptive and no hypothesis was tested. The 
immunologic analysis was based on a per-protocol population, 
which included all subjects who received the vaccine and did 
not have major deviations from the protocol procedure or 
Good Clinical Practices (GCP) violation. If 162 subjects (90% of 
the 180 subjects enrolled) were included in the pre-protocol 
population, the half-width of the 95% confidence interval (CI) 
for GMFR would be 0.15 in the natural log scale, assuming the 
standard deviation of the natural log of the fold rise was 1.0. All 
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subjects who were vaccinated and had safety follow-up were 
included in the safety analysis. If no vaccine-related serious AEs 
were observed among the 180 subjects, this provided 97.5% 
confidence that the true vaccine-related serious AE rate was ≤  
2.03%. 
Ethics statement
The study was approved by the institutional review boards at all 
study sites: Korea University Guro Hospital Institutional Review 
Board (KUGH11261-001), Korea University Ansan Hospital In-
stitutional Review Board (AS11200), Korea University Anam 
Hospital Institutional Review Board (ED11308), Yonsei Univer-
sity Severance Hospital Institutional Review Board (4-2011-0913), 
Kangdong Sacred Heart Hospital Institutional Review Board/
Ethics Committee (12-2-008), The Catholic University of Korea 
Seoul St. Mary’s Hospital Institutional Review Board (XC12MS-
MV0011K), Hanyang University Seoul Hospital Institutional 
Review Board (HYUH IRB 2012-C-15), and Samsung Medical 
Center Institutional Review Board (2012-01-051). Written in-
formed consent was obtained from each subject prior to any 
study procedure. This study was registered at www.clinicaltrial.
gov as NCT01556451.
RESULTS
Characteristics of the study subjects
One hundred eighty subjects were enrolled from April 2012 to 
October 2012. Each study site enrolled 20 subjects. The demo-
graphic characteristics are shown in Table 1. The mean age at 
enrollment was 60.6 ± 6.1 yr. Among the subjects, 91 (50.6%) 
were ≥ 60 yr of age and 136 (75.6%) were female. Approximate-
ly 64% of subjects had one or more underlying medical condi-
tions. The most common underlying condition was vascular 
disorders (32.2%), followed by metabolism and nutrition disor-
ders (21.7%), and musculoskeletal and connective tissue disor-
ders (17.2%). Throughout the study the most frequently report-
ed concomitant prescription medications were analgesics (21.1%), 
agents acting on the renin–angiotensin system (20.0%), lipid-
modifying agents (19.4%), and calcium channel blockers (13.9%). 
Two subjects were administered influenza vaccine between days 
1 and 42.
Immunogenicity
Protocol deviation or GCP violation occurred in 14 (7.8%) sub-
jects among the 180 subjects vaccinated. As a result, the immu-
nologic analysis was performed with 166 subjects. The GMT at 
Day 1 was 66.9 (Table 2). At 4 weeks post-vaccination, the GMT 
for this population was 185.4, with a GMFR of 2.8 (95% CI, 2.5-
3.1). The inverse cumulative distribution of VZV antibody titer 
is shown in Fig. 1. In subgroup analysis according to the age 
group, the GMT for subjects 50-59 yr of age at 4 weeks post-vac-
cination was 173.0, with a GMFR of 2.9 (95% CI, 2.5-3.4). The 
GMT for subjects ≥ 60 yr of age at 4 weeks post-vaccination 
was 199.2, with a GMFR of 2.6 (95% CI, 2.3-3.0). The inverse cu-
mulative distribution of gpELISA fold rise at 4 weeks post-vacci-
nation according to the age group is shown in Fig. 2.
Safety
Table 3 summarizes AEs that occurred during the 42 days after 
Table 1. Baseline characteristics of the study subjects
Characteristics
Total (n = 180)
No. %
Gender
   Female 136 75.6
   Male 44 24.4
Age (yr)
   50-59 89 49.4
  ≥ 60 91 50.6
  ≥ 70 12 6.7
   Median (range) 60 (50-82)
Underlying medical conditions 115 63.9
   Vascular disorders 58 32.2
     Hypertension 55 30.6
   Metabolism and nutritional disorders 39 21.7
     Hyperlipidemia 26 14.3
     Diabetes mellitus 16 8.9
   Musculoskeletal diseases 31 17.2
     Osteoarthritis 5 2.8
     Osteoporosis 5 2.8
     Spinal stenosis 5 2.8
   Gastrointestinal diseases 21 11.7
     Colonic polyp 6 3.3
     Gastroesophageal reflux disease 5 2.8
     Gastritis 4 2.2
   Nervous system disorders 14 7.8
   Renal and urinary disorders 5 2.8
   Cardiac disorders (excluding hypertension) 5 2.8
   Respiratory disorders 4 2.2
With one or more concomitant vaccinations 2 1.1
   Influenza vaccine 2 1.1
Table 2. Varicella-zoster virus antibody geometric mean titers and geometric mean 
fold rise in the per-protocol population
Age group
No. of 
subjects
Results* 95% CI†
Overall GMT (units/mL) Day 1 166 66.9 59.2-75.5
Week 4 166 185.4 167.0-205.9
GMFR Week 4 166 2.8 2.3-3.1
50-59 yr GMT (units/mL) Day 1 84 58.7 49.6-69.4
Week 4 84 173.0 149.2-200.6
GMFR Week 4 84 2.9 2.5-3.4
≥ 60 yr GMT (units/mL) Day 1 82 76.4 64.1-91.2
Week 4 82 199.2 171.5-231.3
GMFR Week 4 82 2.6 2.3-3.0
*Antibody measured as gpELISA units/mL; †95% CI for GMFR and GMT was comput-
ed based on the t-distribution. CI, confidence interval; GMT, geometric mean titer in 
gpELISA units/mL; GMFR, geometric mean fold rise. 
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the vaccinations. Of the 180 subjects vaccinated, 113 (62.8%) 
subjects experienced ≥ 1 AE, with 96 (53.3%) of subjects re-
porting injection-site AEs. The most frequently reported injec-
tion-site AEs were erythema (45.0%) (Table 4). All injection-site 
AEs except for one were determined to be related to the vac-
cine. Most (85.7%) of injection-site AEs were mild in intensity 
and there was no severe event. Most of the injection-site ery-
thema (93.8%) and swelling (95.6%) were ≤ 3 inches in size and 
no case exceeded 5 inches. The injection-site AEs were more 
frequent in subjects 50-59 yr of age (58.4%) than those ≥ 60 yr of 
age (48.4%). Overall, 44 (24.4%) subjects experienced ≥ 1 sys-
temic AE and 10 (5.5%) subjects experienced a systemic vac-
cine-related AE. The most frequently reported systemic AEs 
were rash (3.9%). The systemic AEs were slightly more frequent 
in subjects 50-59 yr of age (25.8%) than those ≥ 60 yr of age 
(23.1%). Three (1.7%) subjects experienced ≥ 1 severe adverse 
Table 3. Adverse events among all study subjects 
Adverse events
Total (n = 180)
No. % 95% CI†
Subjects with one or more AEs 113 62.8 55.3-69.9
   With one or more injection site AEs 96 53.3
   With systemic AEs 44 24.4
Subjects with AEs related to the vaccine* 97 53.9 46.3-61.3
   With one or more injection site AEs 95 52.8
   With no injection site AEs 10 5.6
Subjects with one or more SAEs 3 1.7 0.4-4.8
Subjects with SAEs related to the vaccine 0 0.0 0.0-0.0
*As determined by the investigator to be related to the vaccine; †95% CI based on 
exact binomial distribution. CI, confidence interval; AE, adverse event; SAE, severe 
adverse event.
Table 4. Classification of adverse events among all study subjects
Adverse events
Total (n = 180)
No. % 95% CI*
Subjects with one or more injection site AEs 96 53.3 45.8-60.8
   Erythema 81 45.0 37.6-52.6
   Swelling 68 37.8 30.7-45.3
   Pain 50 27.8 21.4-34.9
   Tenderness 5 2.8 0.9-6.4
   Pruritus 5 2.8 0.9-6.4
   Feeling hot 2 1.1 0.1-4.0
   Rash 1 0.6 0.0-3.1
   Sensation of heaviness 1 0.6 0.0-3.1
Subjects with one or more systemic AEs 44 24.4 18.4-31.4
General disorders and administration site conditions 50 27.8 21.4-34.9
Skin and subcutaneous tissue disorders 15 8.3 4.7-13.4
Infections and infestations 9 5.0 2.3-9.3
Gastrointestinal disorders 9 5.0 2.3-9.3
Musculoskeletal and connective tissue disorders 7 3.9 1.6-7.9
Eye disorders 3 1.7 0.4-4.8
Nervous system disorders 3 1.7 0.4-4.8
Psychiatric disorders 3 1.7 0.4-4.8
Respiratory, thoracic and mediastinal disorders 3 1.7 0.4-4.8
Injury, poisoning and procedural complications 1 0.6 0.0-3.1
*95% CI based on exact binomial distribution. CI, confidence interval. 
event (SAE): gastric polyp, anal fissure, and spinal compression 
fracture. None of these SAEs were classified as related to the 
vaccine. Most (> 90%) of the AEs, except SAEs, subsided in 2 
days. No subjects reported a VZV-like rash. There were no deaths 
and no subjects discontinued due to an adverse event. 
DISCUSSION
This study was performed to evaluate the safety, tolerability, 
and immunogenicity of ZOSTAVAXTM in Korean adults ≥ 50 yr 
of age. Because previous studies did not specifically target Ko-
rean subjects for enrollment, this is the first study to evaluate 
the characteristics of the zoster vaccine in Korean adults. All 
subjects were completely followed up for 42 days and reliable 
results were obtained.
 In immunologic analysis performed in the per-protocol pop-
Fig. 1. Inverse Cumulative Distribution of Varicella-zoster Virus (VZV) Antibody Titer in 
the per-protocol (PP) group. VZV glycoprotein enzyme-linked immunosorbent assay 
(gpELISA) antibody titers (units/mL) were observed clearly increased after the vacci-
nation with ZOSTAVAXTM in the PP group.
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ulation, the GMT was 66.9 at pre-vaccination and 185.4 at 4 weeks 
post-vaccination, with a GMFR of 2.8 (95% CI, 2.5-3.1). In sub-
group analysis, the GMFR at 4 weeks post-vaccination was 2.9 
(95% CI, 2.5-3.4) for subjects 50-59 yr of age and 2.6 (95% CI, 
2.3-3.0) for those ≥ 60 yr of age. The GMFR observed in this 
study is higher than previous studies. ZEST, performed with 
subjects 50-59 yr of age, showed a GMFR of 2.3 (95% CI, 2.2-2.4) 
(16). SPS, performed with subjects ≥ 60 yr of age, showed a 
GMFR of 1.7 (95% CI, 1.6-1.8) (15). The most important reason 
for the difference is considered to be the difference between 
the timing of post-vaccination blood sampling. In two prior 
studies, the VZV-specific immune responses were measured at 
6 weeks post-vaccination (15,16). Racial difference might be 
another reason for study differences; the previous two studies 
did not include Asian countries. Although this study showed 
that the immunogenicity of the zoster vaccine is good in Korean 
adults, the efficacy and the effectiveness of the vaccine for pre-
venting zoster should be assessed with further studies.
 In the safety analysis performed on all subjects, most of the 
AEs were due to local injection-site reactions and their intensity 
was mild. The safety profile of the vaccine in Korean adults was 
similar to previous studies.
 In conclusion, a single dose of zoster vaccine induced VZV-
specific gpELISA antibody response and was generally well-tol-
erated in healthy Korean adults ≥ 50 yr of age. These findings 
are consistent with data previously observed in the clinical de-
velopment program. 
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